Timing of adverse events during maintenance treatment with rucaparib for recurrent ovarian cancer in the phase III ARIEL3 study
dc.contributor.author | Dean, A. | |
dc.contributor.author | Oza, A. M. | |
dc.contributor.author | Lorusso, D. | |
dc.contributor.author | Aghajanian, C. | |
dc.contributor.author | Oaknin, A. | |
dc.contributor.author | Colombo, N. | |
dc.contributor.author | Weberpals, J. | |
dc.contributor.author | Clamp, Andrew R | |
dc.contributor.author | Scambia, G. | |
dc.contributor.author | Leary, A. | |
dc.contributor.author | Holloway, R. W. | |
dc.contributor.author | Gancedo, M. A. | |
dc.contributor.author | Fong, P. C. | |
dc.contributor.author | Goh, J. C. | |
dc.contributor.author | O'Malley, D. M. | |
dc.contributor.author | Cameron, T. | |
dc.contributor.author | Maloney, L. | |
dc.contributor.author | Goble, S. | |
dc.contributor.author | Coleman, R. L. | |
dc.contributor.author | Ledermann, J. A. | |
dc.date.accessioned | 2020-12-08T05:36:30Z | |
dc.date.available | 2020-12-08T05:36:30Z | |
dc.date.issued | 2020 | en |
dc.identifier.citation | Dean A, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Colombo N, et al. 821P Timing of adverse events during maintenance treatment with rucaparib for recurrent ovarian cancer in the phase III ARIEL3 study. Annals of Oncology. 2020;31:S620-S1. | en |
dc.identifier.doi | 10.1016/j.annonc.2020.08.960 | en |
dc.identifier.uri | http://hdl.handle.net/10541/623482 | |
dc.description.abstract | Background: Maintenance treatment with the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib significantly improved progression-free survival vs placebo regardless of biomarker status in patients with recurrent ovarian cancer in the phase III ARIEL3 study (NCT01968213). This exploratory analysis evaluated the timing of treatment-emergent adverse events (TEAEs). Methods: Patients were randomised 2:1 to receive oral rucaparib (600 mg twice daily) or placebo until disease progression, unacceptable toxicity or other reason for discontinuation. Time to onset of TEAEs was assessed. Results: Of the 564 patients randomised in ARIEL3, 561 patients (372 for rucaparib and 189 for placebo) were included in the safety population (updated visit cut-off date, 31 December 2017). Median duration of treatment was 8.3 months for rucaparib and 5.5 months for placebo. Overall, 15.3% of patients receiving rucaparib and 1.6% of patients receiving placebo discontinued treatment due to TEAEs (excluding disease progression). Safety data, including median time to onset of the first event, for TEAEs occurring in 35% of patients are presented in the table. Conclusions: In the rucaparib group, median time to first onset for most of the frequently reported non-haematological TEAEs was within 1 month of therapy. In the rucaparib and placebo groups, median time to first onset of anaemia/decreased haemoglobin occurred within 3 and 2 months of therapy, respectively. | en |
dc.language.iso | en | en |
dc.relation.url | https://dx.doi.org/10.1016/j.annonc.2020.08.960 | en |
dc.title | Timing of adverse events during maintenance treatment with rucaparib for recurrent ovarian cancer in the phase III ARIEL3 study | en |
dc.type | Meetings and Proceedings | en |
dc.contributor.department | Department of Oncology, St John of God Subiaco Hospital, Subiaco, Australia | en |
dc.identifier.journal | Annals of Oncology | en |
dc.description.note | en] | |
refterms.dateFOA | 2020-12-08T13:56:46Z |